Silvio Danese (S Danese)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 144

Top Venues

Alimentary pharmacology & therapeutics

Journal of Crohn's & colitis

Expert opinion on biological therapy

Journal of clinical medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Silvio Danese, Jacinda Tran, Geert D'Haens, David T Rubin, Nobuo Aoyama, Wen Zhou, Dapo Ilo, Xuan Yao, Yuri Sanchez Gonzalez, Remo Panaccione
Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data. Inflammatory bowel diseases (2023)
Sarah Bencardino, Ferdinando D'Amico, Ilaria Faggiani, Francesca Bernardi, Mariangela Allocca, Federica Furfaro, Tommaso Lorenzo Parigi, Alessandra Zilli, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese
Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis. Journal of clinical medicine 12 (15) (2023)
Jacopo Fanizza, Ferdinando D'Amico, Gaetano Lauri, Samuel J Martinez-Dominguez, Mariangela Allocca, Federica Furfaro, Alessandra Zilli, Gionata Fiorino, Tommaso Lorenzo Parigi, Simona Radice, Laurent Peyrin-Biroulet, Silvio Danese
The role of filgotinib in ulcerative colitis and Crohn's disease. Immunotherapy (2023)
Sara Massironi, Giacomo Mulinacci, Camilla Gallo, Chiara Viganò, Maria Fichera, Andrea Villatore, Giovanni Peretto, Silvio Danese
The oft-overlooked cardiovascular complications of inflammatory bowel disease. Expert review of clinical immunology (2023)
Gaetano Lauri, Ferdinando D'Amico, Mariangela Allocca, Diego Palumbo, Emanuel Della-Torre, Francesco De Cobelli, Claudio Doglioni, Paolo Giorgio Arcidiacono, Gabriele Capurso, Silvio Danese
Ustekinumab as induction and maintenance therapy in patients with inflammatory bowel disease and type II autoimmune pancreatitis: report of two cases. Journal of Crohn's & colitis (2023)
Loris Riccardo Lopetuso, Sara Deleu, Lihi Godny, Valentina Petito, Pierluigi Puca, Federica Facciotti, Harry Sokol, Gianluca G Ianiro, Luca Masucci, Maria Abreu, Iris Dotan, Samuel Paul Costello, Ailsa Hart, Tariq H Iqbal, Sudarshan Paramsothy, Maurizio Sanguinetti, Silvio Danese, Herbert Tilg, Fabio Cominelli, Theresa T Pizarro, Alessandro Armuzzi, Giovanni Cammarota, Antonio Gasbarrini, Severine Vermeire, Franco Scaldaferri
The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease. Gut (2023)
Ferdinando D'Amico, Fernando Magro, Britta Siegmund, Taku Kobayashi, Paulo Gustavo Kotze, Virginia Solitano, Benedicte Caron, Sameer Al Awadhi, Ailsa Hart, Vipul Jairath, Axel Dignass, Laurent Peyrin-Biroulet, Silvio Danese
Disease Clearance as a New Outcome in Ulcerative Colitis: a Systematic Review and Expert Consensus. Inflammatory bowel diseases (2023)
Bénédicte Caron, Vipul Jairath, Valérie Laurent, Jaap Stoker, Andrea Laghi, Geert R D'Haens, Silvio Danese, Laurent Peyrin-Biroulet
Defining magnetic resonance imaging treatment response and remission in Crohn's disease: a systematic review. Journal of Crohn's & colitis (2023)
Stefan Schreiber, Gerhard Rogler, Mamoru Watanabe, Severine Vermeire, Christian Maaser, Silvio Danese, Margaux Faes, Paul Van Hoek, Jeremy Hsieh, Ulrik Moerch, Yan Zhou, Angela de Haas, Christine Rudolph, Alessandra Oortwijn, Edward V Loftus
Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE. Alimentary pharmacology & therapeutics (2023)
Sara Massironi, Giacomo Mulinacci, Camilla Gallo, Chiara Viganò, Maria Fichera, Andrea Villatore, Giovanni Peretto, Silvio Danese
The oft-overlooked cardiovascular complications of inflammatory bowel disease. Expert review of clinical immunology (2023)
Francesco Vito Mandarino, Emanuele Sinagra, Dario Raimondo, Silvio Danese
The Role of Microbiota in Upper and Lower Gastrointestinal Functional Disorders. Microorganisms 11 (4) (2023)
Antonio Tursi, Daniele Piovani, Giovanni Brandimarte, Francesco Di Mario, Walter Elisei, Marcello Picchio, Leonardo Allegretta, Maria Laura Annunziata, Mauro Bafutto, Gabrio Bassotti, Maria Antonia Bianco, Raffaele Colucci, Rita Conigliaro, Dan L Dumitrascu, Ricardo Escalante, Luciano Ferrini, Giacomo Forti, Marilisa Franceschi, Maria Giovanna Graziani, Frank Lammert, Giovanni Latella, Giovanni Maconi, Debora Compare, Gerardo Nardone, Lucia Camara De Castro Oliveira, Enio Chaves Oliveira, Alfredo Papa, Savvas Papagrigoriadis, Anna Pietrzak, Stefano Pontone, Tomas Poskus, Giuseppe Pranzo, Matthias Christian Reichert, Stefano Rodinò, Jaroslaw Reguła, Giuseppe Scaccianoce, Franco Scaldaferri, Roberto Vassallo, Costantino Zampaletta, Angelo Zullo, Erasmo Spaziani, Stefanos Bonovas, Silvio Danese, null null
Diverticular Inflammation and Complication Assessment classification, CODA score and fecal calprotectin in clinical assessment of patients with diverticular disease: A decision curve analysis. United European gastroenterology journal (2023)
Pablo Andres Olivera, Juan S Lasa, Giovanni Peretto, Stephane Zuily, Silvio Danese, Laurent Peyrin Biroulet
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs. Alimentary pharmacology & therapeutics (2023)
Stefan Schreiber, David T Rubin, Siew C Ng, Laurent Peyrin-Biroulet, Silvio Danese, Irene Modesto, Xiang Guo, Chinyu Su, Kenneth K Kwok, Hyejin Jo, Yan Chen, Arne Yndestad, Walter Reinisch, Marla C Dubinsky
Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme. Journal of Crohn's & colitis (2023)
Kenji Watanabe, Laurent Peyrin-Biroulet, Silvio Danese, Yasushi Fujitani, Margaux Faes, Alessandra Oortwijn, James O Lindsay, Gerhard Rogler, Toshifumi Hibi
Impact of Concomitant Thiopurine on the Efficacy and Safety of Filgotinib in Patients with Ulcerative Colitis: Post hoc Analysis of the Phase 2b/3 SELECTION Study. Journal of Crohn's & colitis (2023)
Gaetano Lauri, Ferdinando D'Amico, Mariangela Allocca, Diego Palumbo, Emanuel Della-Torre, Francesco De Cobelli, Claudio Doglioni, Paolo Giorgio Arcidiacono, Gabriele Capurso, Silvio Danese
Ustekinumab as induction and maintenance therapy in patients with inflammatory bowel disease and type II autoimmune pancreatitis: report of two cases. Journal of Crohn's & colitis (2023)
Pauline Wils, Silvio Danese, Laurent Peyrin-Biroulet
Promising phase II biologics for future Crohn's disease therapy. Expert opinion on investigational drugs (2023)
Ferdinando D'Amico, Sara Massironi, Mariangela Allocca, Silvio Danese
Advancing transmural remission as a treatment target in Crohn's disease: The future of tight-control strategy? United European gastroenterology journal (2023)
Sara Massironi, Pierpaolo Sileri, Silvio Danese
Get Fit: Muscle Health for Crohn's Disease Surgical Outcome Optimization. Inflammatory bowel diseases (2023)
Francesco Vito Mandarino, Emanuele Sinagra, Dario Raimondo, Silvio Danese
The Role of Microbiota in Upper and Lower Gastrointestinal Functional Disorders. Microorganisms 11 (4) (2023)
Bénédicte Caron, Vipul Jairath, Ferdinando D'Amico, Sameer Al Awadhi, Axel U Dignass, Ailsa L Hart, Taku Kobayashi, Paulo Gustavo Kotze, Fernando Magro, Britta Siegmund, Kristine Paridaens, Silvio Danese, Laurent Peyrin-Biroulet
International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients. Medicina (Kaunas, Lithuania) 59 (1) (2023)
Silvio Danese, Remo Panaccione, Maria T Abreu, David T Rubin, Subrata Ghosh, Axel Dignass, Anita Afzali, Douglas C Wolf, Michael V Chiorean, Severine Vermeire, Anjali Jain, Lorna Charles, Garrett Lawlor, Mark T Osterman, Hsiuanlin Wu, James B Canavan, Ann Katrin Petersen, Jean Frederic Colombel, Miguel Regueiro
Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the True North open-label extension. Journal of Crohn's & colitis (2023)
Ferdinando D'Amico, Fernando Magro, Benedicte Caron, Axel U Dignass, Vipul Jairath, Ailsa Hart, Paulo Gustavo Kotze, Kristine Paridaens, Sameer Al Awadhi, Taku Kobayashi, Britta Siegmund, Laurent Peyrin-Biroulet, Silvio Danese
iSTART-II: An Update on the i Support Therapy-Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis. Journal of clinical medicine 12 (3) (2023)
Bénédicte Caron, Vipul Jairath, Ferdinando D'Amico, Sameer Al Awadhi, Axel U Dignass, Ailsa L Hart, Taku Kobayashi, Paulo Gustavo Kotze, Fernando Magro, Britta Siegmund, Kristine Paridaens, Silvio Danese, Laurent Peyrin-Biroulet
International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients. Medicina (Kaunas, Lithuania) 59 (1) (2023)
Séverine Vermeire, Virginia Solitano, Laurent Peyrin-Biroulet, Herbert Tilg, Silvio Danese, Hartmut Ehrlich, Didier Scherrer, Paul Gineste, Laurence d'Agay, Bruce E Sands
Obefazimod: A First-in-class Drug for the Treatment of Ulcerative Colitis. Journal of Crohn's & colitis (2023)
Bénédicte Caron, Vipul Jairath, Ferdinando D'Amico, Sameer Al Awadhi, Axel U Dignass, Ailsa L Hart, Taku Kobayashi, Paulo Gustavo Kotze, Fernando Magro, Britta Siegmund, Kristine Paridaens, Silvio Danese, Laurent Peyrin-Biroulet
International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients. Medicina (Kaunas, Lithuania) 59 (1) (2023)
Sailish Honap, Anne Buisson, Silvio Danese, Beaugerie Laurent, Laurent Peyrin-Biroulet
Patient and Public Involvement in Research: Lessons for Inflammatory Bowel Disease. Journal of Crohn's & colitis (2023)
Laura Neurath, Ferdinando D'Amico, Silvio Danese
Emerging drugs for the treatment of moderately to severely active ulcerative colitis: Review of phase II and III clinical trials. Expert opinion on emerging drugs (2023)
Gaetano Lauri, Ferdinando D'Amico, Mariangela Allocca, Diego Palumbo, Emanuel Della-Torre, Francesco De Cobelli, Claudio Doglioni, Paolo Giorgio Arcidiacono, Gabriele Capurso, Silvio Danese
Ustekinumab as induction and maintenance therapy in patients with inflammatory bowel disease and type II autoimmune pancreatitis: report of two cases. Journal of Crohn's & colitis (2023)
Stefan Schreiber, Silvio Danese, Axel Dignass, Eugeni Domènech, Massimo C Fantini, Marc Ferrante, Jonas Halfvarson, Ailsa Hart, Fernando Magro, Charlie W Lees, Salvo Leone, Marieke J Pierik, Michele Peters, Polly Field, Helen Fishpool, Laurent Peyrin-Biroulet
Defining Comprehensive Disease Control for use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations. Journal of Crohn's & colitis (2023)
Ferdinando D'Amico, Sophie Vieujean, Benedicte Caron, Laurent Peyrin-Biroulet, Silvio Danese
Risk-Benefit of IBD Drugs: A Physicians and Patients Survey. Journal of clinical medicine 12 (9) (2023)
Francesco Vito Mandarino, Emanuele Sinagra, Dario Raimondo, Silvio Danese
The Role of Microbiota in Upper and Lower Gastrointestinal Functional Disorders. Microorganisms 11 (4) (2023)
Sophie Vieujean, Edouard Louis, Silvio Danese, Laurent Peyrin-Biroulet
A critical review of ustekinumab for the treatment of active ulcerative colitis in adults. Expert review of gastroenterology & hepatology (2023)
Ferdinando D'Amico, Laurent Peyrin-Biroulet, Silvio Danese
Disease Clearance is not Synonymous with Cure. Inflammatory bowel diseases (2023)
Nicole Piazza O Sed, Daniele Noviello, Elisabetta Filippi, Francesco Conforti, Federica Furfaro, Mirella Fraquelli, Andrea Costantino, Silvio Danese, Maurizio Vecchi, Gionata Fiorino, Mariangela Allocca, Flavio Caprioli
Superior predictive value of transmural over endoscopic severity for colectomy risk in ulcerative colitis: a multicenter prospective cohort study. Journal of Crohn's & colitis (2023)
Laura Neurath, Ferdinando D'Amico, Silvio Danese
Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials. Expert opinion on emerging drugs (2023)
Achuthan Aruljothy, Siddharth Singh, Neeraj Narula, Gordon William Moran, Sudheer K Vuyyuru, Malcolm Hogan, Alexa Zayadi, John K MacDonald, Benedicte Caron, Silvio Danese, Laurent Peyrin Biroulet, Christopher Ma, Vipul Jairath
Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis. Alimentary pharmacology & therapeutics (2023)
Stefan Schreiber, Brian G Feagan, Laurent Peyrin-Biroulet, Séverine Vermeire, Margaux Faes, Kristina Harris, Alessandra Oortwijn, Patrick Daniele, Haridarshan Patel, Silvio Danese
Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from SELECTION. Journal of Crohn's & colitis (2023)
Sophie Vieujean, James O Lindsay, Ferdinando D'Amico, Vineet Ahuja, Mark S Silverberg, Ajit Sood, Jesus K Yamamoto-Furusho, Masakazu Nagahori, Mamoru Watanabe, Ioannis E Koutroubakis, Kalliopi Foteinogiannopoulou, Irit Avni Biron, Alissa Walsh, An Outtier, Rie Louise Møller Nordestgaard, Maria T Abreu, Marla Dubinsky, Corey A Siegel, Edouard Louis, Iris Dotan, Walter Reinisch, Silvio Danese, David T Rubin, Laurent Peyrin-Biroulet
Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases (IBD): Real World Results from the International Organization for the study of IBD. Journal of Crohn's & colitis (2023)
Laurent Peyrin Biroulet, Severine Vermeire, Geert D'Haens, Julian Panes, Axel U Dignass, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana Bravatà, Frederic Lavie, Marco Daperno, Milan Lukáš, Alessandro Armuzzi, Mark Löwenberg, Daniel R Gaya, Silvio Danese
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST. Alimentary pharmacology & therapeutics (2023)
Silvio Danese, Virginia Solitano, Vipul Jairath, Laurent Peyrin Biroulet
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance. Nature reviews. Gastroenterology & hepatology 20 (3) (2023)
Remo Panaccione, Eric B Collins, Gil Y Melmed, Severine Vermeire, Silvio Danese, Peter D R Higgins, Christina S Kwon, Wen Zhou, Dapo Ilo, Dolly Sharma, Yuri Sanchez Gonzalez, Si-Tien Wang
Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis. Crohn's & colitis 360 5 (2) (2023)
Francesco Vito Mandarino, Emanuele Sinagra, Dario Raimondo, Silvio Danese
The Role of Microbiota in Upper and Lower Gastrointestinal Functional Disorders. Microorganisms 11 (4) (2023)
Paolo Angelo Cortesi, Gionata Fiorino, Lorenzo Giovanni Mantovani, Silvio Danese
Editorial: treat-to-target in ulcerative colitis clinical management-a small price to pay? Authors' reply. Alimentary pharmacology & therapeutics 57 (5) (2023)
Ferdinando D'Amico, Fernando Magro, Benedicte Caron, Axel U Dignass, Vipul Jairath, Ailsa Hart, Paulo Gustavo Kotze, Kristine Paridaens, Sameer Al Awadhi, Taku Kobayashi, Britta Siegmund, Laurent Peyrin-Biroulet, Silvio Danese
iSTART-II: An Update on the i Support Therapy-Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis. Journal of clinical medicine 12 (3) (2023)
Bénédicte Caron, Vipul Jairath, Ferdinando D'Amico, Sameer Al Awadhi, Axel U Dignass, Ailsa L Hart, Taku Kobayashi, Paulo Gustavo Kotze, Fernando Magro, Britta Siegmund, Kristine Paridaens, Silvio Danese, Laurent Peyrin-Biroulet
International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients. Medicina (Kaunas, Lithuania) 59 (1) (2023)
Remo Panaccione, Silvio Danese, Wen Zhou, Justin Klaff, Dapo Ilo, Xuan Yao, Gweneth Levy, Peter D R Higgins, Edward V Loftus, Su Chen, Yuri Sanchez Gonzalez, Carolyn Leonard, Xavier Hébuterne, James O Lindsay, Qian Cao, Hiroshi Nakase, Jean Frederic Colombel, Séverine Vermeire
Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis. Alimentary pharmacology & therapeutics (2023)
Ferdinando D'Amico, Virginia Solitano, Fernando Magro, Pablo Andres Olivera, Jonas Halfvarson, David T Rubin, Axel Dignass, Sameer Al Awadhi, Taku Kobayashi, Natália Souza Freitas Queiroz, Marta Calvo, Paulo Gustavo Kotze, Subrata Ghosh, Laurent Peyrin-Biroulet, Silvio Danese
Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus. Journal of clinical medicine 12 (19) (2023)
Bram Verstockt, Severine Vermeire, Laurent Peyrin-Biroulet, Rebecca A Mosig, Brian G Feagan, Jean-Frederic Colombel, Britta Siegmund, Florian Rieder, Stefan Schreiber, Andres Yarur, Remo Panaccione, Marla Dubinsky, Simon Lichtiger, Fabio Cataldi, Silvio Danese
The Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study. Journal of Crohn's & colitis (2023)
Geert D'Haens, Michael Eberhardson, Zeljko Cabrijan, Silvio Danese, Remco van den Berg, Mark Löwenberg, Gionata Fiorino, P Richard Schuurman, Göran Lind, Per Almqvist, Peder S Olofsson, Kevin J Tracey, Stephen B Hanauer, Ralph Zitnik, David Chernoff, Yaakov A Levine
Neuroimmune modulation through vagus nerve stimulation reduces inflammatory activity in Crohn's disease patients: a prospective open label study. Journal of Crohn's & colitis (2023)
William J Sandborn, Jingjing Chen, Krisztina Kisfalvi, Edward V Loftus, Geert D'Haens, Ninfa Candela, Karen Lasch, Douglas C Wolf, Sharif M Uddin, Silvio Danese
Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies. Crohn's & colitis 360 5 (3) (2023)
Remo Panaccione, Eric B Collins, Gil Y Melmed, Severine Vermeire, Silvio Danese, Peter D R Higgins, Christina S Kwon, Wen Zhou, Dapo Ilo, Dolly Sharma, Yuri Sanchez Gonzalez, Si-Tien Wang
Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis. Crohn's & colitis 360 5 (2) (2023)
Ferdinando D'Amico, Fernando Magro, Benedicte Caron, Axel U Dignass, Vipul Jairath, Ailsa Hart, Paulo Gustavo Kotze, Kristine Paridaens, Sameer Al Awadhi, Taku Kobayashi, Britta Siegmund, Laurent Peyrin-Biroulet, Silvio Danese
iSTART-II: An Update on the i Support Therapy-Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis. Journal of clinical medicine 12 (3) (2023)
Roger Feakins, Paulo Borralho Nunes, Ann Driessen, Ilyssa O Gordon, Nina Zidar, Pamela Baldin, Britt Christensen, Silvio Danese, Naoimh Herlihy, Marietta Iacucci, Maurice B Loughrey, Fernando Magro, Aart Mookhoek, Magali Svrcek, Francesca Rosini
Definitions of histological abnormalities in inflammatory bowel disease: an ECCO position paper. Journal of Crohn's & colitis (2023)
Sara Massironi, Chiara Viganò, Silvio Danese
Letter: Mendelian randomization - new perspective in inflammatory bowel disease and pancreatic cancer? Authors' reply. Alimentary pharmacology & therapeutics 58 (1) (2023)
Ferdinando D'Amico, Sophie Vieujean, Benedicte Caron, Laurent Peyrin-Biroulet, Silvio Danese
Risk-Benefit of IBD Drugs: A Physicians and Patients Survey. Journal of clinical medicine 12 (9) (2023)
Clotilde Remy, Bénédicte Caron, Celia Gouynou, Vincent Haghnejad, Elodie Jeanbert, Patrick Netter, Silvio Danese, Laurent Peyrin-Biroulet
Inflammatory Bowel Disease Patients' Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience. Journal of clinical medicine 11 (24) (2022)
Clotilde Remy, Bénédicte Caron, Celia Gouynou, Vincent Haghnejad, Elodie Jeanbert, Patrick Netter, Silvio Danese, Laurent Peyrin-Biroulet
Inflammatory Bowel Disease Patients' Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience. Journal of clinical medicine 11 (24) (2022)
Silvio Danese, Laurent Peyrin-Biroulet
Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise. Inflammatory bowel diseases 27 (12) (2022)
Sara Massironi, Ilaria Fanetti, Chiara Viganò, Lorena Pirola, Maria Fichera, Laura Cristoferi, Gabriele Capurso, Invernizzi Pietro, Silvio Danese
Systematic review-pancreatic involvement in inflammatory bowel disease. Alimentary pharmacology & therapeutics 55 (12) (2022)
Ferdinando D'Amico, Olga Tasopoulou, Gionata Fiorino, Alessandra Zilli, Federica Furfaro, Mariangela Allocca, Pierpaolo Sileri, Antonino Spinelli, Laurent Peyrin-Biroulet, Silvio Danese
Early Biological Therapy in Operated Crohn's Disease Patients Is Associated With a Lower Rate of Endoscopic Recurrence and Improved Long-term Outcomes: A Single-center Experience. Inflammatory bowel diseases (2022)
Marc Ferrante, Peter M Irving, Christian Philipp Selinger, Geert R A M D'Haens, Tanja Kuehbacher, Ursula E Seidler, Savion Gropper, Thomas Haeufel, Sebastiano Forgia, Silvio Danese, Jochen Klaus, Brian G Feagan
Safety and tolerability of spesolimab in patients with ulcerative colitis. Expert opinion on drug safety (2022)
Ferdinando D'Amico, Silvio Danese, Gionata Fiorino
Could small molecules be used in combination with biologics for inflammatory bowel disease? Expert review of clinical immunology 18 (10) (2022)
Cecilia Dell'Avalle, Ferdinando D'Amico, Roberto Gabbiadini, Arianna Dal Buono, Nicola Pugliese, Alessandra Zilli, Federica Furfaro, Gionata Fiorino, Mariangela Allocca, Laurent Peyrin-Biroulet, Silvio Danese
JAK inhibitors in crohn's disease: ready to go? Expert opinion on investigational drugs 31 (2) (2022)
Kevin L Winthrop, Arne Yndestad, Dan Henrohn, Silvio Danese, Sara Marsal-Barril, Maria Galindo, John C Woolcott, Hyejin Jo, Kenneth Kwok, Andrea B Shapiro, Thomas V Jones, Annette Diehl, Chinyu Su, Julian Panes, Stanley B Cohen
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatology and therapy (2022)
Silvio Danese, Virginia Solitano, Vipul Jairath, Laurent Peyrin Biroulet
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance. Nature reviews. Gastroenterology & hepatology (2022)
Clotilde Remy, Bénédicte Caron, Celia Gouynou, Vincent Haghnejad, Elodie Jeanbert, Patrick Netter, Silvio Danese, Laurent Peyrin-Biroulet
Inflammatory Bowel Disease Patients' Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience. Journal of clinical medicine 11 (24) (2022)
Silvio Danese, Barrett G Levesque, Brian G Feagan, Alina Jucov, B R Bhandari, Rish K Pai, Kristen Taylor Meadows, Brian J Kirby, Jean-Marie Bruey, Allan Olson, Robin Osterhout, Courtney Van Biene, Julia Ford, Richard Aranda, Kartik Raghupathi, William J Sandborn
Editorial: protecting hypoxia-inducible factor 1a and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis? Authors' reply. Alimentary pharmacology & therapeutics 55 (6) (2022)
Mariangela Allocca, Silvio Danese
Editorial: an accurate, reliable and responsive ultrasound activity score for Crohn's disease? Sounds good to US. Authors' reply. Alimentary pharmacology & therapeutics 55 (3) (2022)
Kevin L Winthrop, Arne Yndestad, Dan Henrohn, Silvio Danese, Sara Marsal-Barril, Maria Galindo, John C Woolcott, Hyejin Jo, Kenneth Kwok, Andrea B Shapiro, Thomas V Jones, Annette Diehl, Chinyu Su, Julian Panes, Stanley B Cohen
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatology and therapy 10 (2) (2022)
Lucas Guillo, Laurent Peyrin Biroulet, Silvio Danese
Editorial: shedding new light on extraintestinal manifestations in inflammatory bowel disease. Alimentary pharmacology & therapeutics 55 (9) (2022)
Stefan Schreiber, Peter M Irving, Ala I Sharara, María Dolores Martín-Arranz, Xavier Hébuterne, Plamen Penchev, Silvio Danese, Prodromos Anthopoulos, Gamar Akhundova-Unadkat, Filip Baert
Review article: randomised controlled trials in inflammatory bowel disease-common challenges and potential solutions. Alimentary pharmacology & therapeutics 55 (6) (2022)
Silvio Danese, Barrett G Levesque, Brian G Feagan, Alina Jucov, Bal Raj Bhandari, Rish K Pai, Kristen Taylor Meadows, Brian J Kirby, Jean-Marie Bruey, Allan Olson, Robin Osterhout, Courtney Van Biene, Julia Ford, Richard Aranda, Kartik Raghupathi, William J Sandborn
Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1α stabiliser, for treatment of ulcerative colitis. Alimentary pharmacology & therapeutics 55 (4) (2022)
Paolo Angelo Cortesi, Gionata Fiorino, Laurent Peyrin Biroulet, Lorenzo Giovanni Mantovani, Vipul Jairath, Kristine Paridaens, Fredrik L Andersson, Silvio Danese
Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mild-moderate ulcerative colitis. Alimentary pharmacology & therapeutics (2022)
Bénédicte Caron, Valérie Laurent, Freddy Odille, Silvio Danese, Gabriela Hossu, Laurent Peyrin-Biroulet
New magnetic resonance imaging sequences for fibrosis assessment in Crohn's disease: a pilot study. Scandinavian journal of gastroenterology 57 (12) (2022)
Kevin L Winthrop, Arne Yndestad, Dan Henrohn, Silvio Danese, Sara Marsal-Barril, Maria Galindo, John C Woolcott, Hyejin Jo, Kenneth Kwok, Andrea B Shapiro, Thomas V Jones, Annette Diehl, Chinyu Su, Julian Panes, Stanley B Cohen
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatology and therapy (2022)
Clotilde Remy, Bénédicte Caron, Celia Gouynou, Vincent Haghnejad, Elodie Jeanbert, Patrick Netter, Silvio Danese, Laurent Peyrin-Biroulet
Inflammatory Bowel Disease Patients' Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience. Journal of clinical medicine 11 (24) (2022)
Kevin L Winthrop, Arne Yndestad, Dan Henrohn, Silvio Danese, Sara Marsal-Barril, Maria Galindo, John C Woolcott, Hyejin Jo, Kenneth Kwok, Andrea B Shapiro, Thomas V Jones, Annette Diehl, Chinyu Su, Julian Panes, Stanley B Cohen
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatology and therapy 10 (2) (2022)
Sara Massironi, Chiara Viganò, Silvio Danese
Letter: pancreatic involvement in inflammatory bowel disease-authors' reply. Alimentary pharmacology & therapeutics 56 (2) (2022)
Alessandro Mannucci, Ferdinando D'Amico, Ahmad El Saadi, Laurent Peyrin-Biroulet, Silvio Danese
Filgotinib for moderately to severely active ulcerative colitis. Expert review of gastroenterology & hepatology 16 (10) (2022)
Eduardo Mysler, Valderilio Feijó Azevedo, Silvio Danese, Daniel Alvarez, Noriko Iikuni, Beverly Ingram, Markus Mueller, Laurent Peyrin Biroulet
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? Drugs 81 (16) (2021)
Virginia Solitano, Tommaso Lorenzo Parigi, Elisa Ragaini, Silvio Danese
Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents. Expert opinion on investigational drugs 30 (10) (2021)
Silvio Danese, Kavitha Subramaniam, Jan Van Zyl, Shashi Adsul
Editorial: vedolizumab in inflammatory bowel diseases-less is more? Authors' reply. Alimentary pharmacology & therapeutics 53 (3) (2021)
Silvia D'Alessio, Federica Ungaro, Daniele Noviello, Sara Lovisa, Laurent Peyrin Biroulet, Silvio Danese
Revisiting fibrosis in inflammatory bowel disease: the gut thickens. Nature reviews. Gastroenterology & hepatology (2021)
Tommaso Lorenzo Parigi, Virginia Solitano, Laurent Peyrin-Biroulet, Silvio Danese
Do JAK inhibitors have a realistic future in treating Crohn's disease? Expert review of clinical immunology 18 (3) (2021)
Virginia Solitano, Ludovico Alfarone, Ferdinando D'Amico, Laurent Peyrin-Biroulet, Silvio Danese
IBD goes home: from telemedicine to self-administered advanced therapies. Expert opinion on biological therapy (2021)
Rodrigo Borrega, Carlos Araújo, Nádia Aguiam, Fernando Magro, João Eurico Fonseca, Silvio Danese, João A Lopes, Joao Goncalves
Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 35 (1) (2021)
David T Rubin, Irene Modesto, Séverine Vermeire, Silvio Danese, William K K Wu, Kenneth K Kwok, Nana Koram, Thomas V Jones
Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis. Alimentary pharmacology & therapeutics (2021)
Bénédicte Caron, Patrick Netter, Silvio Danese, Laurent Peyrin-Biroulet
Bispecific antibodies for the treatment in inflammatory bowel disease: an avenue worth exploring? Expert opinion on biological therapy (2021)
William J Sandborn, Nervin Lawendy, Silvio Danese, Chinyu Su, Edward V Loftus, Ailsa Hart, Iris Dotan, Adérson O M C Damião, Donna T Judd, Xiang Guo, Irene Modesto, Wenjin Wang, Julian Panés
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Alimentary pharmacology & therapeutics (2021)
Ferdinando D'Amico, Christian Rabaud, Laurent Peyrin Biroulet, Silvio Danese
SARS-CoV-2 vaccination in IBD: more pros than cons. Nature reviews. Gastroenterology & hepatology 18 (4) (2021)
Mariangela Allocca, Vincenzo Craviotto, Cecilia Dell'Avalle, Federica Furfaro, Alessandra Zilli, Ferdinando D'Amico, Stefanos Bonovas, Laurent Peyrin Biroulet, Gionata Fiorino, Silvio Danese
Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn's disease. Alimentary pharmacology & therapeutics (2021)
Pablo A Olivera, Stéphane Zuily, Paulo Gustavo Kotze, Veronique Regnault, Sameer Al Awadhi, Peter Bossuyt, Richard B Gearry, Subrata Ghosh, Taku Kobayashi, Patrick Lacolley, Edouard Louis, Fernando Magro, William K K Wu, Alfredo Papa, Timothy Raine, Fabio V Teixeira, David T Rubin, Silvio Danese, Laurent Peyrin Biroulet
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nature reviews. Gastroenterology & hepatology 18 (12) (2021)
HoUng Kim, Rieke E Alten, J R Fraser Cummings, Silvio Danese, Geert R A M D'Haens, Paul Emery, Subrata Ghosh, Cyrielle Gilletta de Saint Joseph, Jong Hyuk Lee, James O Lindsay, Elena Nikiphorou, Ben Parker, Stefan Schreiber, Steven R A Simoens, René Westhovens, Ji Hoon Jeong, Laurent Peyrin-Biroulet
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. mAbs 13 (1) (2021)
Daniele Piovani, Silvio Danese, Laurent Peyrin Biroulet, Georgios K Nikolopoulos, Stefanos Bonovas
Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease. Alimentary pharmacology & therapeutics 51 (9) (2020)
Ferdinando D'Amico, Tommaso Lorenzo Parigi, Stefanos Bonovas, Laurent Peyrin-Biroulet, Silvio Danese
Long-term safety of approved biologics for ulcerative colitis. Expert opinion on drug safety 19 (7) (2020)
Silvio Danese, Bruce E Sands, William K K Wu, Laurent Peyrin Biroulet
The day after COVID-19 in IBD: how to go back to 'normal'. Nature reviews. Gastroenterology & hepatology 17 (8) (2020)
Eric Gracey, Lars Vereecke, Dermot McGovern, Mareike Fröhling, Larissa Valor-Méndez, Silvio Danese, Martine De Vos, Filip Van den Bosch, Dirk Elewaut
Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis. Nature reviews. Rheumatology 16 (8) (2020)
Sébastien Daude, Thomas Remen, Thomas Chateau, Silvio Danese, Isabelle Gastin, Cédric Baumann, Jean Louis Gueant, Laurent Peyrin Biroulet
Comparative accuracy of ferritin, transferrin saturation and soluble transferrin receptor for the diagnosis of iron deficiency in inflammatory bowel disease. Alimentary pharmacology & therapeutics 51 (11) (2020)
Ferdinando D'Amico, Gionata Fiorino, Federica Furfaro, Mariangela Allocca, Giulia Roda, Laura Loy, Alessandra Zilli, Virginia Solitano, Laurent Peyrin-Biroulet, Silvio Danese
Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach. Expert review of gastroenterology & hepatology 14 (9) (2020)

Silvio Danese.css-eqlu8i{font-size:small;padding-left:4px;} (S Danese)

Publication Activity (10 Years)

Top Topics

Top Venues

Silvio Danese (S Danese)